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Abstract
 
Sclerosteosis, a skeletal disorder characterized by high bone mass due to increased osteoblast activity,
is caused by loss of the 
 
SOST
 
 gene product, sclerostin. The localization in bone and the mechanism
of action of sclerostin are not yet known, but it has been hypothesized that it may act as a bone
morphogenetic protein (BMP) antagonist. We show here that 
 
SOST
 
/sclerostin is expressed
exclusively by osteocytes in mouse and human bone and inhibits the differentiation and miner-
alization of murine preosteoblastic cells (KS483). Although sclerostin shares some of the actions
of the BMP antagonist noggin, we show here that it also has actions distinctly different from it.
In contrast to noggin, sclerostin did not inhibit basal alkaline phosphatase (ALP) activity in
KS483 cells, nor did it antagonize BMP-stimulated ALP activity in mouse C2C12 cells. In
addition, sclerostin had no effect on BMP-stimulated Smad phosphorylation and direct tran-
scriptional activation of MSX-2 and BMP response element reporter constructs in KS483 cells.
Its unique localization and action on osteoblasts suggest that sclerostin may be the previously
proposed osteocyte-derived factor that is transported to osteoblasts at the bone surface and
inhibits bone formation.
Key words: sclerosteosis • 
 
SOST
 
 • osteoblast • Smad phosphorylation • MSC
 
Introduction
 
Sclerosteosis (OMIM 269500) is a rare sclerosing skeletal
disorder characterized by generalized progressive bone
overgrowth leading to tall stature, facial distortion, entrapment
of cranial nerves, and raised intracranial pressure that pre-
disposes to sudden death (1–4). Syndactyly, radial deviation
of terminal phalanges, and dysplasia of the nails are variable
manifestations. The majority of patients belong to the Afri-
kaner population of South Africa (5), but several patients
have been described in other parts of the world (6–13). In
sclerosteosis, bone formation is increased, whereas bone
resorption is not affected or mildly diminished (11, 14). Bone
biopsies from patients exhibit predominance of cuboidal
active-appearing osteoblasts, increased double tetracycline
label spacing, and increased osteoid levels that mineralize
normally. Serum alkaline phosphatase (ALP) levels are ele-
vated in some, but not all patients.
Recently, sclerosteosis was found to result from loss of
the 
 
SOST
 
 gene product sclerostin, a newly cloned gene
localized on chromosome region 17q12-q21 (15, 16). Van
Buchem disease (OMIM 239100), a condition resembling
sclerosteosis but differentiated by its less severe character
and absence of hand malformations (3, 5) was recently
found to result from a homozygous 52-kb deletion some
35-kb downstream of the 
 
SOST
 
 gene (17, 18). Absence of
any evidence for a gene within this deleted region suggests
that loss of regulatory elements within the 52-kb deletion
results in down-regulation of 
 
SOST
 
 expression. These
 
Address correspondence to R.L. van Bezooijen, Dept. of Endocrinology,
C4-R, Leiden University Medical Center, Albinusdreef 2, 2333 ZA
Leiden, Netherlands. Phone: 31-71-5263076; Fax: 31-71-5248136;
email: R.L.van_Bezooyen@lumc.nl
Portions of this work were presented at the 24th Annual Meeting of
the American Society for Bone and Mineral Research in San Antonio,
TX on 20–24 September 2002.
 
Abbreviations used in this paper:
 
 ALP, alkaline phosphatase; BMP, bone
morphogenetic protein; BRE, BMP response element; CoM, control
medium; MSC, mesenchymal stromal cell; PTHrP, parathyroid hormone-
related protein; SF9, 
 
Spodoptera frugiperda
 
. 
Osteocyte-expressed Sclerostin Inhibits Bone Formation
 
806
 
data suggest that 
 
SOST
 
/sclerostin is a regulator of bone
mass in humans.
However, the localization of 
 
SOST
 
/sclerostin expression
in bone and the mechanism by which it affects bone forma-
tion are yet unknown. The amino acid sequence of scleros-
tin shares similarity with the cystine knot–containing factors
belonging to the DAN family of secreted glycoproteins (16,
19). The DAN family includes DAN, cerberus, gremlin,
protein related to DAN, and cerberus, caronte, and dante
that share the ability to antagonize bone morphogenetic
protein (BMP) activity (20, 21). BMPs are stimulators of
bone formation and their activity is controlled at several lev-
els, including extracellular antagonists that bind BMPs and
prevent their binding to signaling receptors (22, 23). Of
these BMP antagonists, noggin and gremlin have been
shown to regulate osteoblastic differentiation and function.
Together, these data suggest that increased bone formation
in patients with sclerosteosis may be due to unopposed
BMP-stimulated osteoblastic activity (16). BMPs elicit the
cellular responses via specific BMP types I and II serine/
threonine kinase receptors and their downstream transcrip-
tion effector proteins called Smads (24).
Therefore, in the present work, we examined the local-
ization and mechanism of action of sclerostin, and we show
that it is exclusively expressed in osteocytes and inhibits the
bone-forming activity of osteoblasts by a mechanism differ-
ent from that described for classic BMP antagonists.
 
Materials and Methods
 
Compounds. 
 
Human sclerostin and control medium (CoM)
were provided by D.G. Winkler (Celltech Inc., Bothell, WA).
Sclerostin was purified using a Heparin Hitrap column (Amer-
sham Biosciences) from conditioned medium of insect 
 
Spodoptera
frugiperda
 
 (SF9) cells infected with human 
 
SOST
 
 sequence. CoM
of uninfected SF9 cells was handled similar to the medium of
 
SOST
 
 expressing SF9 cells. Recombinant human BMPs were
purchased from R&D Systems and parathyroid hormone-related
protein (PTHrP) 1–34 was obtained from Bacham AG.
 
Isolation of Total RNA. 
 
RNA isolation was performed ac-
cording to the method described by Chomczynski and Sacchi
(25). Human bone biopsies from a femur head of an adult male, a
mastoid from a patient with sclerosteosis, and mouse tibiae of
young adult (8 wk old) female Swiss albino mice were cleaned
from connective tissue and snap frozen in liquid nitrogen. The
frozen bone biopsies were pulverized in liquid nitrogen cooled in
7-ml stainless steel flasks at 1,500 revolutions/min for 2 min using
a Braun Mikro-Dismembrator U (Salm en Kipp N.V.). Pulver-
ized bones were resuspended in 4 M guanidinium isothiocyanate
lysis buffer and centrifuged at 6,000 revolutions/min for 10 min
to remove bone grit. RNA isolation from cells was performed as
described previously (26).
 
RT-PCR. 
 
Denatured RNA was reverse transcribed into
cDNA and standardized by competitive PCR using internal stan-
dards (mouse pMUS and human pQB-2) as described previously
(26). Subsequently, expression of various genes was examined by
semi-quantitative PCR. cDNA was denatured at 94
 
 
 
C for 3 min
followed by repeated cycles of 30 s at 94
 
 
 
C, 45 s at 56
 
 
 
C, and 30 s
at 72
 
 
 
C. Primer sets used crossed intron/exon boundaries so that
eventual contaminations with genomic DNA would not be am-
 
plified in the amplification process or would generate amplicons of
larger size. Primer sets used were as follows: human 
 
 
 
2
 
-micro-
globulin, sense, 5
 
 
 
-CCAGCAGAGAATGGAAAGTC-3
 
 
 
, antisense,
5
 
 
 
-GATGCTGCTTACATGTCTCG-3
 
 
 
; mouse 
 
 
 
2
 
-microglob-
ulin, sense, 5
 
 
 
-TGACCGGCTTGTATGCTATC-3
 
 
 
, antisense,
5
 
 
 
-CAGTGTGAGCCAGGATATAG-3
 
 
 
; human osteocalcin,
sense, 5
 
 
 
-GTAGTGAAGAGACCCAGGCG-3
 
 
 
, antisense, 5
 
 
 
-
GGGAAGAGGAAAGAAGGGTG-3
 
 
 
; mouse osteocalcin primer
set 1, sense, 5
 
 
 
-TCTGACAAAGCCTTCATGTCC-3
 
 
 
, anti-
sense, 5
 
 
 
-CGCATCTACGGTATCACTATTT-3
 
 
 
; mouse os-
teocalcin primer set 2, sense, 5
 
 
 
-GCAGCTTGGTGCACAC-
CTAG-3
 
 
 
, antisense, 5
 
 
 
-ATGGATGTCACAGCACGCTCC-
3
 
 
 
; human 
 
SOST
 
, sense, 5
 
 
 
-CCGGAGCTGGAGAACAA-
CAAG-3
 
 
 
, antisense, 5
 
 
 
-GCACTGGCCGGAGCACACC-3
 
 
 
;
and mouse 
 
SOST
 
, sense, 5
 
 
 
-TCCTCCTGAGAACAACCA-
GAC-3
 
 
 
, antisense, 5
 
 
 
-TGTCAGGAAGCGGGTGTAGTG-3
 
 
 
.
 
Radioactive In Situ Hybridization. 
 
8-wk-old female Swiss al-
bino mice were fixed in vivo with 2% paraformaldehyde, 75 mM
lysine monohydrochloride, and 10 mM sodium periodate in
0.1 M phosphate buffer under general anesthesia (xylazine,
Bayer; ketamine HCl, Eurovet; reference 27). Tibiae and femurs
were removed and decalcified for 2 wk in 10% EDTA and 0.5%
paraformaldehyde. 17-d-old mouse embryos were fixed in 3.7%
phosphate-buffered formaldehyde, pH 7.2, for 5 d. 5-
 
 
 
m-thick
sections were prepared from paraffin-embedded blocks of decal-
cified mouse tibiae and femurs and undecalcified mouse embryos.
In situ hybridization was performed as described previously
with some modifications (27). 
 
 
 
-[
 
35
 
S]CTP–labeled mouse sense
and antisense SOST probes were generated from 
 
SOST
 
 cDNA
containing pCR2.1 vectors provided by K. Staehling-Hampton
(Celltech Inc., Bothell, WA). Sections were hybridized overnight
with 
 
 
 
-[
 
35
 
S]CTP labeled probes at 60
 
 
 
C. Sections were coated
with K5 emulsion (Ilford Limited), developed with Kodak D19,
and fixed with Kodak Unifix.
 
Immunohistochemistry. 
 
Human bone biopsies from 6 patients
with sclerosteosis and 16 control subjects were obtained after sur-
gical treatment and fixed in 4% phosphate-buffered formaldehyde
and 70% ethanol before decalcification in 17% formic acid and
2.6% sodium formate. 5-
 
 
 
m-thick paraffin sections were stained as
described previously (27). Primary mouse monoclonal IgG-1
 
 
 
 an-
tibodies generated against full-length human sclerostin were pro-
vided by D.G. Winkler and used at a 1:1,000 dilution. Osteoclasts
were stained using TRAcP staining as a marker. For this, naphthol
ASBI phosphate was used as substrate, pararosaniline was used as a
coupler, and 30 mM L
 
 
 
-tartaric acid was used as an inhibitor (28).
 
Cell Line Cultures. 
 
Mouse preosteoblastic KS483 cells form
mineralized bone nodules when cultured under osteogenic cul-
tures conditions; i.e., in 
 
 
 
MEM without phenol red (GIBCO
BRL) supplemented with 10% FCS (Integro), 50 
 
 
 
g/ml ascorbic
acid from day 3 or 4 onwards (Merck), and 10 mM 
 
 
 
-glycero-
phosphate from day 10 onwards (Sigma-Aldrich; references 29–
32). KS483 cells were seeded at a density of 15,000 cells/cm
 
2
 
, and
agents were added when cells reached confluence after 3 or 4 d of
culture. In short-term experiments, ALP activity was measured
kinetically in the cell layer after another 4 d of culture (31). In
long-term differentiation experiments, ALP activity and mineral-
ization were analyzed by ALP and alizarin red staining, respec-
tively (31). Medium was renewed every 3 to 4 d.
Mouse myoblastic C2C12 cells were seeded at a density of
20,000 cells/cm
 
2
 
 and cultured until confluence (3 or 4 d of culture)
in DMEM and 20% FCS. At confluence, FCS serum concentra-
tion was reduced to 5%, and agents were added. ALP activity was
measured kinetically in the cell layer after another 4 d of culture. 
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Mesenchymal Stromal Cell (MSC) Cultures. 
 
Mouse bone mar-
row–derived MSCs were obtained from young adult (8 wk old)
female Swiss albino mice by removing both ends of the femora
and tibia and subsequent flushing with PBS. Cells were resus-
pended to obtain a single cell suspension and seeded at a density of
1.67 
 
 
 
 10
 
6
 
 cells/cm
 
2
 
 in 
 
 
 
MEM, 10% heat-inactivated FCS, 50
 
 
 
g/ml ascorbic acid, and 10 mM 
 
 
 
-glycerophosphate from day 13
onwards. Two-thirds medium was renewed every 3 to 4 d.
Liquid nitrogen stored Ficoll-separated human bone marrow
cells from healthy donors obtained by aspiration from the poste-
rior iliac crest were provided by W.A. Noort (Leiden University
Medical Center, Leiden, Netherlands; reference 33). Thawed hu-
man bone marrow cells were seeded at a density of 
 
 
 
 10
 
7
 
 cells/
25 cm
 
2
 
 culture flask in 8 ml 
 
 
 
MEM and 10% heat-inactivated
FCS and allowed to attach without disturbance for 7 d. After the
attachment period, half of the culture medium was renewed at
3–4 d intervals until cultures reached subconfluence (after 
 
 
 
 2
wk). The enriched human bone marrow–derived MSCs were re-
seeded at a density of 2.5 
 
 
 
 10
 
4
 
 cells/cm
 
2
 
 in 
 
 
 
MEM, 10% heat-
inactivated FCS, 50 
 
 
 
g/ml ascorbic acid, 10
 
 
 
7
 
 M dexamethasone
(Organon N.V.), and 5 mM 
 
 
 
-glycerophosphate from day 7 on-
wards. Medium was renewed every 3–4 d. In short-term experi-
ments, cells were stimulated after 4 d of culture (i.e., at conflu-
ence), and ALP activity was measured kinetically in the cell layer
after another 4 d of culture.
 
Transfections and Reporter Assays. 
 
KS483 cells were seeded at
a density of 10,000/cm
 
2
 
 in 24-well plates and transiently trans-
fected with 1 
 
 
 
g of the BMP-responsive luciferase reporter con-
struct MSX-2 (34) or BMP response element (BRE; reference
35) using Fugene™6 transfection reagent (Roche) according to
the manufacturer’s protocol. To correct for transfection effi-
ciency, 100 ng of 
 
Renilla
 
 luciferase vector (pRL-SV40; Promega)
was cotransfected. 12 h after transfection, the medium was
changed for medium containing 0.2% FCS. The cells were kept
in 0.2% FCS medium for 1 d and left either nonstimulated or
stimulated for an additional 24 h. Luciferase assays were per-
formed with the Dual-Luciferase Reporter assay system (Promega)
according to the manufacturer’s instructions. 10 
 
 
 
l of cell lysate
was first assayed for firefly luciferase and then for 
 
Renilla
 
 luciferase
activity, using the Wallac 1450 Microbeta Trilux luminescence
counter (PerkinElmer). Firefly luciferase activity was corrected
for 
 
Renilla
 
 luciferase activity to control for differences in transfec-
tion efficiency.
 
Smad Phosphorylation.
 
KS483 cells were seeded at a density of
15,000 cells/cm
 
2
 
 and cultured until confluence when FCS con-
centration was reduced to 0.2%. The next day, cultures were
stimulated for 45 min with the agents indicated. Phosphorylated
Smad-1, -5, and/or -8 were detected specifically by phospho–
Smad-1 antibodies as described previously (36).
 
Statistics. 
 
Values are expressed as mean 
 
 
 
 SEM. Statistical
differences between values were examined by one-way analysis of
variance followed by Tukey’s multiple comparison test and con-
sidered to be significantly different at P 
 
 
 
 0.05.
 
Results
 
SOST mRNA Expression in Human and Mouse Bone.
Total RNA was isolated from mouse and human bone and
from bone of a patient with sclerosteosis. Using RT-PCR,
SOST mRNA expression was found in tibia of young adult
mice and a human femur head obtained during hip replace-
ment (Fig. 1 A). SOST mRNA expression was also found in
mastoid of a patient with sclerosteosis from South Africa,
suggesting that the mutation found in these patients does not
lead to an increased degradation of SOST mRNA. Sequence
analysis confirmed that the amplified mouse and human scle-
rostin amplicons were from sclerostin mRNA origin.
To locate expression in bone, we further studied SOST
mRNA expression using radioactive in situ hybridization
on sections. In 17.5-d-old mouse embryos, SOST mRNA
was expressed in all mineralized bones (i.e., the palatal shelf;
Fig. 1, B–D). The expression pattern of SOST mRNA was
confirmed with a second RNA probe directed to an un-
translated region of SOST mRNA. In 5-d-old neonatal ul-
nae, radii, and tail vertebrae and in tibia of young adult
mice, SOST mRNA expression was restricted to osteocytes
with the highest expression in the center of cortical bone
(Fig. 1, E–G). SOST mRNA expression was not found in
articular cartilage at any of the examined stages.
Sclerostin Protein Expression in Human Bone.  To study
sclerostin expression at the protein level, bone biopsies of
18 control subjects were analyzed with a panel of 30
Figure 1. Localization of SOST mRNA expression in vivo. RT-PCR
analysis of SOST mRNA expression in tibia of a young adult mouse, human
hipbone, and mastoid of a patient with sclerosteosis (A). Amplicons were
amplified over 35 cycles and had the predicted size of 185 bp. In situ
hybridization analysis of SOST mRNA expression in 17.5-d-old fetal
mouse embryos (B–D) and adult mouse tibia (E–G). Goldner staining of
the upper and lower jaw to visualize mineralized bone (B, green/blue).
Details of the palatal shelf in the upper jaw showing specific SOST
mRNA expression in mineralized bone using antisense probe against
SOST (C) and sense probe as control (D). Goldner staining of adult
mouse tibia (E). Specific SOST mRNA expression in osteocytes using
antisense probe against SOST (F) and sense probe as control (G). Coun-
terstaining was hematoxylin and eosin (C, D, F, and G). Magnification is
(B) 40, (C and D) 200, and (E–G) 100. (1) Nasal cavity. (2) Nasopharynx.
(3) Oropharynx. (4) Tongue. (5) Nose. (6) Mandible. B, Bone. BM,
bone marrow. M, muscle. MW, 100-bp molecular weight marker. NC,
negative control. PC, positive control.Osteocyte-expressed Sclerostin Inhibits Bone Formation 808
monoclonal antibodies against human sclerostin. Eight of
these clones showed exclusive sclerostin staining in osteo-
cytes in both cortical and trabecular bone, whereas the
other clones were negative for specific sclerostin staining
(Fig. 2, A and B). Clones H7 and H11 provided the stron-
gest signals. High power magnification showed that the
osteocyte canaliculi and/or lacunae were positive for scle-
rostin expression (Fig. 2 C). Sclerostin expression was
found in osteocytes in bone biopsies from adults (range
28–69 yr; Fig. 2, A–C) as well as children (range 6 mo–12
yr; Fig. 2 D). Importantly, no sclerostin staining was ob-
served in lining cells or active bone-forming osteoblasts.
Furthermore, articular (Fig. 2, E and F) cartilage was nega-
tive for sclerostin staining.
Specificity of sclerostin signal was demonstrated by the ab-
sence of any binding with clones H7 and H11 in bone biop-
sies of six patients with sclerosteosis from South Africa (Fig. 2
G). These patients should not express sclerostin due to a stop
codon in the first exon of the SOST gene caused by a C69T
transition (16). Note the predominance of cuboidal active-
appearing osteoblasts that are characteristic for sclerosteosis
bone. Staining with a mouse monoclonal antibody of the
same isoform IgG-1  against human PECAM-1/CD31
showed no signal in osteocytes, whereas blood vessels in the
same bone biopsy stained positive (unpublished data).
SOST/Sclerostin Is Not Expressed in Osteoclasts.  To in-
vestigate whether or not SOST mRNA and sclerostin are
expressed in osteoclasts, we studied SOST/sclerostin ex-
pression in combination with TRAcP staining to identify
osteoclasts in mouse and human bone. No SOST mRNA
expression was found in TRAcP  osteoclasts in 17-d-old
mouse embryos, whereas it was found in the bone collars of
these ribs that were devoid of osteoclasts (Fig. 3, A–C). In
postnatal mouse bones, SOST mRNA expression was also
not found in TRAcP  osteoclasts (unpublished data). Sim-
ilarly, we have never seen any TRAcP  osteoclasts being
positive for sclerostin expression in any of the postnatal or
adult human bone biopsies studied, whereas osteocytes
were positive (Fig. 3, D and E).
SOST mRNA Expression during Osteoblast Differentiation
In Vitro.  The presence of SOST mRNA expression in
mineralized bone during embryogenesis and the restricted
expression of SOST mRNA and sclerostin protein in osteo-
cytes postnatally suggested a differentiation dependent ex-
pression of the gene. To examine this, we studied the onset
of SOST mRNA expression during osteoblastic differentia-
tion of mouse and human bone marrow–derived MSCs and
of mouse preosteoblastic KS483 cells. All these cells differ-
entiate into mature osteoblasts that form a mineralized ma-
trix when cultured under osteogenic conditions, including
ascorbic acid and  -glycerophosphate and, in the case of
human MSCs, also dexamethasone. Mouse MSCs formed
ALP positive bone nodules after   7 d of culture and these
nodules mineralized from   12 d onwards. SOST mRNA
expression was analyzed in relation to that of the known os-
Figure 2. Sclerostin protein is expressed by osteocytes in human bone
biopsies. Sclerostin protein expression was analyzed in control and sclerosteo-
sis human bone biopsies using mouse monoclonal antibodies generated
against human sclerostin. Staining with clone H11 showed sclerostin
expression in osteocytes of both trabecular (A) and cortical (B) normal
femur. Canaliculi and/or lacunae of osteocytes were positive for sclerostin
(C). Sclerostin staining of a toe bone biopsy of a 1-yr-old boy showed
clear restricted expression of sclerostin to osteocytes (D). No sclerostin
expression was found in articular cartilage (E and F) of a 12-yr-old girl.
No sclerostin staining was found in mastoid of a patient with sclerosteosis
(G). Note the presence of active bone-forming osteoblasts on the bone
surface that is characteristic for a site of active bone formation. Counter-
staining was Mayers Hematoxylin. C, cartilage. B, bone. Magnification is
(A and B) 40, (C) 400, and (D–G) 100.
Figure 3. Sclerostin protein is not expressed by osteoclasts in mouse and
human bone. Goldner staining of a rib of a 17.5-d-old fetal mouse embryo
(A). Specific SOST mRNA expression in mineralized bone of the rib using
antisense probe against SOST (B). TRAcP staining of the rib showing
that osteoclasts do not colocalize with SOST mRNA expression.
TRAcP  osteoclasts (arrowheads) are present in the bone marrow and on
the surface of the bone collars, whereas SOST mRNA is located within
the bone collar (C). Sclerostin staining of human bone biopsy of a 12-yr-old
girl shows that sclerostin is expressed by osteocytes, but not by multinuclear
osteoclasts on the bone surface (D). TRAcP staining to identify multinuclear
osteoclasts on the bone surface (E). Magnification is (A and B) 100 and
(C–E) 200.van Bezooijen et al. 809
teoblast differentiation marker osteocalcin. In noncultured
mouse bone marrow, day 0, both osteocalcin and SOST
mRNA were not expressed (Fig. 4 A). Induction of osteo-
calcin mRNA expression was seen at day 11 and was further
elevated from day 14 onwards. SOST mRNA expression
was induced after the onset of osteocalcin mRNA expres-
sion and was found from day 14 onwards.
However, mouse MSC cultures consist of a heteroge-
neous cell population. Therefore, we also studied expression
of SOST mRNA in the preosteoblastic KS483 cell line.
Similar to mouse bone marrow cells, these cells formed ALP
positive bone nodules during the first week of culture that
mineralized from   11 d onwards. Osteocalcin mRNA ex-
pression was induced at day 10 of culture and was further
elevated from day 17 onwards (Fig. 4 B). Similar to mouse
MSCs, SOST mRNA expression was induced only after
the onset of osteocalcin mRNA expression and was found
from day 17 onwards. Differentiation of KS483 cells can be
inhibited by treatment with a continuous high dose of 10 8 M
PTHrP (1–34), resulting in the absence of ALP positive and
mineralized bone nodules (32). Addition of PTHrP delayed
and reduced osteocalcin mRNA expression and completely
prevented induction of SOST mRNA.
In vitro, human MSCs do not form bone nodules, but a
rather homogeneous cell layer of ALP positive cells and ar-
eas of more and less condense mineralized matrix. Osteo-
calcin mRNA was already expressed in undifferentiated
cells, and the expression was elevated from day 14 onwards,
which coincides with onset of mineralization (Fig. 4 C).
SOST mRNA expression was not detected in undifferenti-
ated cells and was always detected in late differentiated cells
Figure 4. SOST mRNA is expressed during the mineralization phase
of osteoblastic cultures. Mouse MSCs (A), KS483 cells (B), and human
MSCs (C) were cultured under osteogenic conditions. SOST mRNA
expression during osteoblastic differentiation is shown in relation to the
late osteoblast differentiation marker osteocalcin. Osteocalcin was amplified
over 30, 30, and 35 cycles for mouse MSCs, KS483 cells, and human
MSCs, respectively. The amplicons had the predicted size of 199 bp
(mouse primer set 1), 430 bp (mouse primer set 2), and 242 bp (human
primer set). SOST was amplified over 35, 35, and 40 cycles, respectively,
and the amplicons had the predicted size of 137 bp (mouse primer set)
and 185 bp (human primer set). KS483 cells were cultured in the absence
or presence of 10 8 M PTHrP with continuous treatment from day 4
onwards. MW, 100-bp molecular weight marker. PC, positive control.
Figure 5. Sclerostin inhibits unstimulated and BMP-stimulated osteo-
blastic differentiation of KS483 and primary human MSCs, but not of
C2C12 cells. Silver staining (lanes 1 and 2) and Western blotting with a
rabbit anti–human sclerostin antibody (lanes 3–8) of human sclerostin
(lanes 2 [100 ng/ml], 3 [500 ng/ml], 5 [100 ng/ml], and 7 [100 ng/ml]),
sclerostin containing medium of KS483 (lane 4), CHO cells (lane 6), and
immunodepleted sclerostin preparation (lane 8, equal volume as 100 ng/ml
sclerostin preparation) run under reducing conditions (A). Long-term (18 d)
osteogenic KS483 cell cultures were treated with sclerostin (2.5  g/ml or
concentrations indicated) or CoM (equal volume) from day 4 onwards
and analyzed for ALP activity (B) and mineralization (C). Confluent
KS483 were stimulated with BMPs (50 ng/ml BMP-2, 50 ng/ml BMP-4,
300 ng/ml BMP-5, 100 ng/ml BMP-6, and 300 ng/ml BMP-7) in the
absence or presence of the dose range of sclerostin or CoM. ALP activity
was measured kinetically 4 d after stimulation (D). Confluent C2C12 cells
were stimulated with 50 ng/ml BMP-4 in the absence or presence of the
dose range of sclerostin or CoM. ALP activity was measured kinetically 4 d
after stimulation (E). Confluent hMSCs were stimulated with 100 ng/ml
BMP-4 in the absence or presence of the dose range of sclerostin. ALP
activity was measured kinetically 4 d after stimulation (F). CoM, Control
medium. hMSCs, human mesenchymal stromal cells. MW, molecular
weight marker. Scl, sclerostin. Scl CHO, sclerostin containing medium of
CHO cells. Scl ID, Immunodepleted sclerostin preparation. Scl KS483,
sclerostin containing medium of KS483 cells. Results are expressed as
mean   SEM of triplicate (B and C) or octagonal (D–F) experiments
relative to control (B and C) and BMP stimulation (D–F) that was set at
100%. *, Significant versus CoM (P   0.05). Statistical differences were
omitted from C for clarity.Osteocyte-expressed Sclerostin Inhibits Bone Formation 810
(i.e., 21 d of culture). However, the exact moment of in-
duction of SOST mRNA expression could not be deter-
mined and varied between 10 and 21 d of culture. In addi-
tion, SOST mRNA was expressed at low levels and was
only detected after 40 PCR cycles. In summary, we show
that SOST mRNA was expressed only after ALP and os-
teocalcin expression in all three culture systems, which is
consistent with a differentiation-dependent expression.
This was further supported by the observation that inhibi-
tion of differentiation of KS384 cells by PTHrP also sup-
pressed SOST mRNA induction.
Sclerostin Inhibits Bone-forming Activity of Osteoblasts In
Vitro.  Protein staining and Western blot analysis showed
that the sclerostin preparation contained three bands of
 18, 23, and 30 kD that may correlate to the two possible
N-glycosylation sites of human sclerostin (Fig. 5 A; refer-
ence 16). No other protein bands were found using the
sensitive silver protein staining method, demonstrating its
high degree of purification. The sclerostin preparation ran
similar to sclerostin containing medium of KS483 and
CHO cells with transient and stable expression of human
SOST cDNA, respectively. Using an ELISA-based binding
assay with 200 ng of human sclerostin–coated on the sur-
face or an in vitro binding and covalent cross-linking assay
with iodinated sclerostin, we found that sclerostin bound
BMP-6 dose dependently over a concentration range of
5–400 ng/ml (unpublished data).
To study the effect of sclerostin on the formation of
bone matrix, long-term osteoblastic KS483 cell cultures
were treated with sclerostin at concentrations of 0.025–2.5
 g/ml. As shown in Fig. 5 B, sclerostin slightly but signifi-
cantly inhibited ALP activity only at the highest concentra-
tion used. In contrast, sclerostin had a dramatic inhibitory
effect on calcium deposition (Fig. 5 C). This effect of scle-
rostin is different from that of the BMP antagonist noggin
that inhibited both ALP activity and mineralization com-
pletely at equal concentrations in these cells (31).
We examined the effect of sclerostin in cultures stimu-
lated with BMPs. In KS483 cells, sclerostin dose depen-
dently antagonized the stimulation of ALP activity by two
different subclasses of the BMP family that have the most
pronounced effects on bone formation (i.e., BMP-2 and
BMP-4 vs. BMP-5, BMP-6, and BMP-7; Fig. 5 D). Scle-
rostin did not show any preference for the different BMPs,
nor did it suppress ALP activity below basal level. This again
contrasts the action of noggin that inhibited BMP-stimu-
lated ALP activity below the basal level (31) and showed a
preference for antagonizing BMP-2, -4, and -7 in these cells
(unpublished data). Specificity of the BMP antagonistic ef-
fect of the human sclerostin preparation was proven by loss
of activity after immunodepletion with a rabbit anti–human
sclerostin antibody. Depletion of sclerostin was checked by
Western blotting (Fig. 5 A, lanes 7 and 8).
The aforementioned experiments revealed differences in
the effects of sclerostin and noggin on basal and BMP-stimu-
lated differentiation of preosteoblastic cells. To further exam-
ine this, we used another cell line (i.e., mouse C2C12 cells
that acquire osteoblastic features after BMP stimulation). In
this cell line, sclerostin did not antagonize ALP activity in-
duced by BMP-4 (Fig. 5 E), BMP-2, nor BMP-6 (not de-
picted). Similarly, BMP-induced outgrowth of distal bone
ends and inhibition of chondrocyte differentiation of cultured
fetal mouse metatarsals (37) was not antagonized by sclerostin.
To study whether the observed BMP antagonistic effect
of sclerostin was not restricted to the KS483 cell line, we
tested sclerostin on primary human MSCs. Similar to the
effect on KS483 cells, sclerostin antagonized BMP-4–stim-
ulated ALP activity in primary human MSCs dose depen-
dently (Fig. 5 F).
Although sclerostin’s action was different from that of
noggin, it antagonized BMP activity under some conditions.
To examine the BMP antagonistic activity of sclerostin in
more detail, we studied the effect of sclerostin on early BMP
responses as Smad phosphorylation and direct target gene
transcription. BMP-4–stimulated phosphorylation of Smad-1,
-5, and/or -8 was not antagonized by sclerostin, whereas
it was antagonized by noggin (Fig. 6 A). Similarly, BMP
stimulation of two BMP/Smad-dependent promoter con-
structs (i.e., a luciferase reporter construct containing the
Figure 6. Sclerostin does not antagonize early BMP responses in KS483
cells. Western analysis of Smad-1, -5, and/or -8 phosphorylation in con-
fluent KS483 cells that were stimulated for 45 min with 50 ng/ml BMP-4
in the absence or presence of 2.5  g/ml sclerostin or 500 ng/ml noggin
(A). Subconfluent KS483 cells were transfected with MSX-2 luciferase
reporter construct (B) or BRE luciferase reporter construct (C) and stimu-
lated for 24 h with 100 ng/ml BMP-6 or 50 ng/ml BMP-4 in the absence
or presence of the dose range of sclerostin, CoM, or noggin (500 ng/ml),
respectively. CoM, Control medium. Scl, sclerostin. Smad-P, phosphory-
lated Smad-1, -5, and/or -8. Results are expressed as mean   SEM of
triplicate experiments relative to BMP stimulation that was set at 100%.
*, Significant versus CoM. #, Significant versus BMP-4. P   0.05.van Bezooijen et al. 811
MSX-2 promoter and a synthetic BRE luciferase reporter
construct containing multimerized Smad-binding elements
from the Id-1 promoter) was not antagonized by sclerostin
(Fig. 6, B and C, respectively). However, noggin completely
inhibited BMP-stimulated luciferase activity. These data
were confirmed by examining mRNA expression levels as
sclerostin treatment did not prevent the elevation in MSX-2
and Id-1 mRNA levels 4 h after BMP stimulation, whereas
noggin treatment did (unpublished data).
The observation that sclerostin antagonized the late BMP
response of ALP activity in KS483 cells but not direct BMP
responses suggests that sclerostin may act on or in combina-
tion with a BMP-inducible factor. To study this, sclerostin
was added at several time points after BMP-6 stimulation; it
was found to inhibit ALP activity even when it was added as
long as 24 h after initial BMP stimulation (Fig. 7 A). The
BMP-induced factor may act in synergism with BMPs to
stimulate ALP activity. If this is true, BMP presence is not
only required at the initial time point of stimulation but also
during the culture period after stimulation. To study this, we
removed BMP-4 from the medium or antagonized its activ-
ity at several time points after BMP stimulation by changing
the medium or adding soluble truncated BMP receptor-1A,
respectively. Using both methods, it was found that BMP-4
needed to be present for  24 h to stimulate ALP activity
significantly in KS483 cells (Fig. 7 B). Thereafter, ALP ac-
tivity increased gradually with 72 h of BMP-4 presence be-
ing similar to continuous BMP-4 presence. Similar data
were obtained with BMP-6 (unpublished data).
Discussion
In the present work, we show that sclerostin is a negative
regulator of bone formation that is expressed exclusively in
osteocytes of mouse and human bone and suppresses bone
formation by inhibiting the differentiation of osteoblasts.
Recently, sclerostin was hypothesized to act as a BMP an-
tagonist (16). However, its unique localization and its in-
ability to antagonize several BMP responses in osteoblastic
cells differentiate sclerostin from the classical BMP antago-
nists noggin and gremlin that have also been reported to
play an important role in bone formation (22).
Sclerostin deficiency due to SOST mutations causes scle-
rosteosis (15, 16), a generalized progressive skeletal disorder
characterized by high bone mass due to increased osteoblast
activity (Fig. 8, A and B; references 5, 11, 14). However, the
mechanism by which sclerostin regulates bone formation is
unknown. We show here that SOST mRNA was expressed
in all mineralized bones of both intramembraneous and en-
dochondral origin during mouse embryogenesis. At this early
stage of bone development, it is difficult to determine
whether SOST mRNA expression was restricted to osteo-
cytes or whether osteoblasts expressed SOST mRNA as
well. However, postnatally, it was obvious that SOST
mRNA as well as sclerostin protein expression were re-
stricted to osteocytes in trabecular and cortical bones of both
Figure 7. Time-dependent effects of sclerostin and BMPs on ALP
activity.  Sclerostin antagonizes BMP responses in KS483 cells when
added as long as 24 h after BMP stimulation (A). Confluent KS483 cells
were stimulated with 100 ng/ml BMP-6 in the absence or presence of 1.0
 g/ml sclerostin that was added at the indicated time points after BMP
stimulation. ALP activity was measured kinetically 3 d after stimulation.
BMPs need to be present for  24 h to stimulate ALP activity (B). Confluent
KS483 cells were stimulated with 50 ng/ml BMP-4 for indicated time
periods. BMP-4 was removed from the medium or its activity antago-
nized by changing the medium (light gray bars) or adding soluble truncated
BMP receptor-1A (250 ng/ml; dark gray bars), respectively. ALP activity
was measured kinetically 4 d after stimulation. Results are expressed as
mean   SEM of octagonal experiments. *, Significant versus BMP-6.
#, Significant versus control (P   0.05). strBMPR-1A, soluble truncated
BMP receptor-1A.
Figure 8. Histological pictures and a schematic model of increased
bone formation in sclerosteosis due to sclerostin deficiency. Representative
Goldner staining of calvarial bones of a control (A) and a patient with
sclerosteosis (B). Schematic model of sclerostin’s mechanism of action in
bone remodeling (C). Sclerostin produced by osteocytes may be trans-
ported through lacunae to the bone surface, where it inhibits osteoblastic
bone formation. In sclerosteosis, loss of sclerostin may prolong the active
bone-forming phase of osteoblasts and thereby increase the amount
of bone formed by osteoblasts. The increased osteoid levels in sclerosteo-
sis reflect this. In the absence of increased osteoclastic bone resorption,
the increased bone formation results in a positive bone balance and, sub-
sequently, in the excess bone mass of normal architecture and increased
strength found in sclerosteosis. LC, lining cell. OB, osteoblast. OC, osteoclast.
OCYT, osteocyte.Osteocyte-expressed Sclerostin Inhibits Bone Formation 812
endochondral and intramembraneous origin in mice and hu-
mans. These results are in accordance with RT-PCR find-
ings showing SOST mRNA expression in mouse and hu-
man bone biopsies in the present work as well as in a human
bone biopsy reported previously by Brunkow et al. (16).
Recently, Kusu et al. (38) reported that SOST mRNA is ex-
pressed by osteoclasts based on similarities between patterns
of MMP-9 and SOST mRNA expression in bone samples of
newborn mice. However, here we provide unequivocal evi-
dence that SOST/sclerostin is not expression in osteoclasts in
embryonic, neonatal, and adult mouse and human bone us-
ing in situ hybridization and immunohistochemistry to de-
tect  SOST/sclerostin expression and the classical specific
TRAcP staining method to identify osteoclasts.
Specificity of sclerostin protein expression in human
bone biopsies was demonstrated by the absence of scleros-
tin staining in bone biopsies of six patients with sclerosteo-
sis. Positive sclerostin staining of osteocyte canaliculi and/
or lacunae, with which osteocytes are connected to neigh-
boring osteocytes in an osteon or to osteoblasts and lining
cells on the bone surface, suggests that sclerostin is trans-
ported to neighboring cells (possibly to active bone-form-
ing osteoblasts). This transport might be intracellular from
cell to cell because osteocyte canaliculi are connected at
their tips by gap junctions (39). Alternatively, and perhaps
more likely because of the presence of a putative secretion
signal in sclerostin (16), the transport may occur extracellu-
larly from lacuna to lacuna. The notion that sclerostin is a
secreted protein is supported further by the presence of
sclerostin in culture medium of human SOST cDNA ex-
pressing osteoblastic KS483 cells.
In vitro, SOST mRNA expression was restricted to
the  mineralization phase of osteoblastic cultures. SOST
mRNA levels appeared to be higher in mouse MSCs than
in KS483 cell cultures and were low in human MSC cul-
tures. Low levels of SOST mRNA expression have been
detected previously in late-stage (i.e., 21 d old) primary hu-
man osteoblastic cultures of a male Caucasian donor (15).
Differences in expression levels between the culture sys-
tems used may be related to the absence or presence as well
as the size of bone nodules. Mouse MSC cultures con-
tained bone nodules that were much larger than those
formed in KS483 cultures. In human MSC cultures, bone
nodules did not develop. The relative low levels of SOST
mRNA expression in all three culture systems suggests that
SOST mRNA is restricted to only a few cells, possibly os-
teocytes in the bone nodules. The presence of osteocyte-
like cells in bone nodules has been demonstrated previously
in late mineralized fetal mouse calvaria-derived osteoblastic
cultures (40), and we have indication for the presence of
osteocytes in the bone nodules of mouse MSC cultures as
well (unpublished data). Whether SOST mRNA expres-
sion is more pronounced or restricted to osteocytes in bone
nodules remains to be established.
Because increased bone formation in sclerosteosis results
from sclerostin deficiency, sclerostin is expected to have an
inhibitory effect on bone formation. In the present work, we
show that, in contrast to the BMP antagonist noggin (31),
sclerostin only slightly inhibited the early osteoblast differen-
tiation marker ALP activity. However, similar to noggin,
sclerostin strongly inhibited the formation of mineralized
bone nodules, the end-stage marker of osteoblast activity.
Together, these data suggest that sclerostin produced by os-
teocytes is transported to the bone surface, where it inhibits
the later stages of bone formation (Fig. 8 C). This makes
sclerostin a perfect candidate for the osteocyte-derived factor
that inhibits active bone-forming osteoblasts on the bone
surface as proposed by Marotti (41) and Martin (42). These
investigators suggested that an osteocyte sufficiently covered
by new bone and osteoid sends an inhibitory signal through
their dendritic processes to reduce the bone deposition rate
of osteoblasts. In sclerosteosis, the absence of the inhibitory
signal sclerostin would keep osteoblasts in an active deposi-
tion state and, as a consequence, would increase the deposi-
tion of bone by osteoblasts. This model can thereby explain
the phenotype of sclerosteosis in which loss of sclerostin re-
sults in increased bone formation that is not associated with
increased osteoclastic bone resorption. Alternatively, scleros-
tin may act on the osteocyte itself and inhibit the production
of a signal that inhibits osteoblast activity.
However, the mechanism by which sclerostin produced
by osteocytes inhibits bone formation is yet unknown.
Brunkow et al. (16) suggested that sclerostin may inhibit
bone formation by antagonizing BMP-stimulated osteo-
blast activity. In line with this, sclerostin inhibited BMP-
stimulated ALP activity in mouse osteoblastic KS483 cells.
However, in contrast to the restricted antagonistic activity
of sclerostin for BMP-6 and BMP-7 recently reported by
Kusu et al. (38), we found no obvious differences in the ca-
pacity of sclerostin to inhibit stimulation of ALP activity by
BMP-2, -4, -5, -6, and -7. In addition, and in contrast to
sclerostin’s low binding affinity (10 8 M) for BMPs, Kusu
et al. reported that stimulation of ALP activity by 10 ng/ml
BMP-6 was antagonized by 0.1 ng/ml sclerostin. This is at
least a 1,000-fold lower than in our experience in which
ALP activity stimulated by 100 ng/ml BMP-6 was antago-
nized by 2.5  g/ml sclerostin. Importantly, sclerostin did
not antagonize BMP-stimulated ALP activity in mouse
C2C12 cells and BMP-induced morphological changes in
cultured fetal mouse metatarsals. These data differentiate
sclerostin from the classical BMP antagonists that all inhibit
BMP bioactivity independently of the bioassay used. Con-
firmation of sclerostin being different from the classical
BMP antagonists was provided by its inability to inhibit
BMP stimulation of Smad phosphorylation and BMP/
Smad-dependent reporter constructs MSX-2 and BRE in
KS483 cells. Furthermore, addition of sclerostin 24 h after
BMP stimulation still inhibited ALP activity. The trend to-
ward a better inhibition of BMP-stimulated ALP activity
when sclerostin was added later may be explained by in-
creased instability or loss of bioactivity of sclerostin in me-
dium supplemented with 10% FCS at 37 C.
The observation that sclerostin antagonized the late
BMP response of ALP activity in KS483 cells, but not di-
rect BMP responses may be explained by different mecha-
nisms of action of sclerostin.van Bezooijen et al. 813
First, sclerostin may function as a BMP antagonist only
when a BMP-inducible factor is coexpressed (Fig. 9, Op-
tion I). This cofactor is necessary for sclerostin to prevent
BMP binding to its receptor in such a way that activation
of the receptor is prevented. Such a cofactor may be similar
to twisted gastrulation for the BMP antagonist chordin
(43). This option is supported by sclerostin binding to
BMPs as recently reported by Kusu et al. (38) and also
found by us using ELISA-based binding studies, in vitro
binding, and covalent cross-linking of iodinated sclerostin
to BMP-6 (unpublished data). However, there is a large
difference in the binding affinities of noggin and sclerostin
for BMPs, 10 12 M versus 10 8 M, respectively, that is not
reflected in the small difference in BMP-antagonizing ac-
tivities, 10 5 M versus 10 4 M, respectively. The proposed
BMP-inducible cofactor may increase sclerostin’s binding
affinity for BMPs similar to that of noggin. If true, scleros-
tin may antagonize early BMP responses in cells already ex-
pressing the cofactor, whereas it will not antagonize any
BMP response in cells in which the cofactor cannot be in-
duced, possibly C2C12 cells.
Second, sclerostin may antagonize another yet unknown
BMP-inducible factor that stimulates bone formation (Fig.
9, Option II). This option is supported by the observation
that sclerostin does not have any preference for the different
types of BMPs. In contrast, noggin preferentially antagonizes
BMP-2, -4, and -7. In addition, the differences between the
binding affinities and antagonizing activities of noggin and
sclerostin may also favor the existence of another factor an-
tagonized by sclerostin. This unknown factor may act in
synergism with BMPs because BMPs needed to be present
for  24 h to stimulate ALP activity in KS483 cells.
Alternatively, sclerostin may bind to its own, yet un-
known BMP-inducible receptor and inhibit bone forma-
tion. However, in preliminary experiments, we did not
find any binding of iodinated sclerostin to BMP-stimulated
KS483 cells.
In summary, sclerostin is expressed in osteocytes and in-
hibits bone formation by a mechanism different from that
of known BMP antagonists. Its localization and characteris-
tic of being a secreted protein suggest that sclerostin is
transported to the bone surface, where it inhibits osteoblast
differentiation and function. These observations suggest
that inactivation of sclerostin by small molecules or human-
ized neutralizing antibodies may induce a positive bone
balance, an effect that may have therapeutic implications
for patients with osteoporosis.
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